Study of Panitumumab F(ab')2 for Imaging and Therapy of HER1-positive Cancers
Author Information
Author(s): Wong Karen J, Baidoo Kwamena E, Nayak Tapan K, Garmestani Kayhan, Brechbiel Martin W, Milenic Diane E
Primary Institution: National Cancer Institute, National Institutes of Health
Hypothesis
The study aims to evaluate the in vitro and in vivo properties of the F(ab')2 fragment of panitumumab for imaging and radioimmunotherapy of HER1-positive cancers.
Conclusion
The panitumumab F(ab')2 fragment is a promising candidate for imaging of HER1-positive cancers.
Supporting Evidence
- The F(ab')2 fragment was successfully produced and radiolabeled.
- In vivo studies showed acceptable tumor targeting and normal organ distribution.
- Imaging modalities validated the tumor targeting of the F(ab')2 fragment.
Takeaway
Researchers created a smaller version of a cancer-fighting antibody to help doctors see and treat certain types of cancer better.
Methodology
The F(ab')2 fragment was generated by enzymatic digestion, radiolabeled, and tested in tumor-bearing mice for imaging and targeting.
Limitations
The study primarily focuses on pre-clinical analysis, and results may not directly translate to human applications.
Participant Demographics
The study involved athymic mice bearing LS-174T tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website